Evolution of defining and reinterpretation of cardiotoxicity
█ Review
DOI: 10.26430/CHUNGARICA.2023.53.2.89
Authors:
Czuriga Dániel1, Drobni Zsófia Dóra2, Pozsonyi Zoltán3
1Debreceni Egyetem, Általános Orvostudományi Kar, Kardiológiai Intézet, Kardiológiai Tanszék, Debrecen
2Semmelweis Egyetem, Városmajori Szív- és Érgyógyászati Klinika, Budapest
3Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest
Levelezési cím:
Dr. med. habil. Czuriga Dániel, Debreceni Egyetem, Általános Orvostudományi Kar, Kardiológiai Intézet,
Kardiológiai Tanszék, 4032 Debrecen, Móricz Zsigmond krt. 22. E-mail: dczuriga@med.unideb.hu
Summary
One of the guiding principles of cardio-oncology practice is to minimize the unnecessary interruption of anti-tumour therapy. The overall goal of the specialty is to ensure that cancer patients receive the best possible anticancer therapy safely, while minimizing cancer therapy-related cardiovascular toxicity (CTR-CVT) during oncology care. In this paper, we describe prior and current definitions of CTR-CVT and briefly present the landmark CARDIOTOX registry, as well as corresponding parts of the recently published, first cardio-oncology guideline of the European Society of Cardiology. In our paper, we aim to provide insight into the cardio-oncology-related aspects of precision medicine.
ISSUE: CARDIOLOGIA HUNGARICA | 2023 | VOLUME 53, ISSUE 2
click here to read the full article |
click here to read the pdf |
|
| Watch the video summary |